Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | FYN | P06241 | 6/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12368903 | 0.94 | MET (0.47) | METFYNMKNK1PIM1 | |
| SCHEMBL12368998 | 0.92 | MET (0.54) | METPIM1 | |
| SCHEMBL12369005 | 0.91 | MET (0.53) | METMKNK1PIM1 | |
| SCHEMBL12368885 | 0.90 | MET (0.52) | METMKNK1PIM1 | |
| SCHEMBL12368810 | 0.89 | MET (0.51) | METMKNK1PIM1 | |
| SCHEMBL12368893 | 0.88 | MET (0.50) | METPIM1 | |
| SCHEMBL12368987 | 0.87 | MET (0.49) | METPIM1 | |
| SCHEMBL12368889 | 0.87 | MET (0.49) | METPIM1 | |
| SCHEMBL12368912 | 0.86 | MET (0.48) | METPIM1 | |
| SCHEMBL12368952 | 0.85 | MET (0.43) | METFYNMKNK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | MET 1/4885FYN 183/4885MKNK1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.